All In Biotech

Drug Trial Radar · NCT05459571

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy of Axicabtagene Ciloleucel Concomitant With Prophylactic Steroids In Subjects With Relapsed Or Refractory Large B-Cell Lymphoma In The Outpatient Setting

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

35

Actual

Start

Aug 9, 2022

Primary completion

Nov 24, 2025

Study completion Nov 24, 2025

Sponsor

Lead sponsor
Kite, A Gilead CompanyGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jul 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study was to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.

Conditions

  • Relapsed or Refractory Large B-cell Lymphoma

Interventions

  • Axicabtagene CiloleucelBiological

    Administered intravenously

  • CyclophosphamideDrug

    Administered intravenously

  • FludarabineDrug

    Administered intravenously

  • DexamethasoneDrug

    Administered orally or intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-emergent Cytokine Release Syndrome (CRS) as Per SeverityTime frame: Up to 2.2 years
  2. Percentage of Participants With Treatment-emergent Neurologic Events as Per SeverityTime frame: Up to 2.2 years

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, California

  • UCLA

    Los Angeles, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • Oncology Hematology Care Clinical Trials, LLC

    Cincinnati, Ohio

  • Prisma Health - Upstate

    Greenville, South Carolina

  • Tennessee Oncology, PLLC

    Nashville, Tennessee

  • Henry-Joyce Cancer Clinic

    Nashville, Tennessee

  • Methodist Healthcare System of San Antonio

    San Antonio, Texas

  • Intermountain Healthcare

    Murray, Utah

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah

  • University of Virginia Health System

    Charlottesville, Virginia

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Virginia Commonwealth University

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.